Deal Tracker · Regions

GCC pharma licensing deals

10 licensing deals in the GCC tracked by EPT (2024–2026). Most active: ADCAN Pharma, Elpen, Alvion Pharmaceuticals & Bio-Thera Solutions. Latest: Bukwang Pharmaceutical → NASAQ (Licensing, 4 Nov 2026).

10
deals tracked
9
announced in 2026
$2.7m
disclosed value (1 deal)
100%
licensing, the top deal type
  • EPT has tracked 10 GCC pharma licensing deals (2024–2026), 9 of them announced in 2026.
  • The countries that appear most often are Saudi Arabia (8), UAE (7), Greece (3) & China (2).
  • Values were disclosed for 1 of 10 deals, totalling $2.7m; the largest is Bukwang Pharmaceutical → NASAQ ($2.7m, 4 Nov 2026).
  • The most active companies: ADCAN Pharma (6) & Elpen (2).

Most active companies

ADCAN Pharma (6) · Elpen (2)

Countries involved

Saudi Arabia (8) · UAE (7) · Greece (3) · China (2) · India (2) · Argentina (1)

Largest disclosed deals

Questions

How many GCC pharma licensing deals has EPT tracked?
10 as of 4 Nov 2026, covering 2024–2026; 9 were announced in 2026. The most recent is Bukwang Pharmaceutical → NASAQ (Licensing, 4 Nov 2026).
Which companies are most active in GCC pharma licensing deals?
ADCAN Pharma (6 deals), Elpen (2 deals).
What is the largest disclosed GCC pharma licensing deal?
Bukwang Pharmaceutical → NASAQ: $2.7m (Licensing, 4 Nov 2026). Values are as announced by the parties.
Which countries appear most in GCC pharma licensing deals?
Saudi Arabia (8), UAE (7), Greece (3), China (2), India (2), Argentina (1) — counting where the parties are based and the markets the deals cover.

Browse deals

By region

GCC (83) · MENA (66) · Africa (17) · Latin America (17) · Southeast Asia (17) · Global (LMICs) (14) · CIS & Central Asia (13) · Türkiye (5) · Global ex-US (1)

By country

Saudi Arabia (69) · UAE (61) · China (31) · Egypt (27) · United States (26) · Oman (20) · India (19) · Switzerland (18) · Jordan (14) · South Korea (14) · Kazakhstan (13) · Algeria (12) · Türkiye (12) · United Kingdom (11) · Brazil (10) · Kuwait (10) · Iraq (8) · Morocco (8) · Bahrain (7) · Malaysia (7) · Spain (7) · Argentina (6) · Germany (6) · Indonesia (6) · Philippines (6) · Qatar (6) · Italy (5) · Mexico (5) · Vietnam (5) · France (4) · Taiwan (4) · Tunisia (4) · Canada (3) · Chile (3) · Denmark (3) · Greece (3) · Japan (3) · Lebanon (3) · Nigeria (3) · Pakistan (3) · South Africa (3) · Sweden (3) · Thailand (3) · Azerbaijan (2) · Colombia (2) · Ireland (2) · Kenya (2) · Libya (2) · Netherlands (2) · Singapore (2) · Uruguay (2) · Uzbekistan (2)

By year

2026 (193) · 2025 (27) · 2024 (6) · 2022 (3) · 2021 (2)

By therapeutic area

Multi-therapy (64) · Oncology (30) · Metabolic / Diabetes (27) · Cardiovascular (17) · Vaccines (15) · Immunology / Inflammation (13) · Rare / Orphan (9) · Infectious Disease (8) · CNS / Neurology (6) · Ophthalmology (6) · Consumer health (5) · Women's Health (4) · Respiratory (2)